At the time of writing, Beam Therapeutics Inc [BEAM] stock is trading at $26.81, up 9.34%. An important factor to consider is whether the stock is rising or falling in short-term value. The BEAM shares have gain 9.74% over the last week, with a monthly amount drifted -16.66%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Beam Therapeutics Inc [NASDAQ: BEAM] stock has seen the most recent analyst activity on July 23, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $80. Previously, JP Morgan upgraded its rating to Overweight on January 29, 2024, and elevated its price target to $40. On December 15, 2023, downgrade downgraded it’s rating to Neutral but maintained its price target of $35 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $30 on December 08, 2023. Leerink Partners downgraded its rating to a Market Perform and reduced its price target to $20 on October 20, 2023. Cantor Fitzgerald downgraded its rating to Neutral for this stock on October 20, 2023. In a note dated March 21, 2023, Bernstein initiated an Mkt Perform rating and provided a target price of $37 on this stock.
For the past year, the stock price of Beam Therapeutics Inc fluctuated between $16.95 and $49.50. Currently, Wall Street analysts expect the stock to reach $63 within the next 12 months. Beam Therapeutics Inc [NASDAQ: BEAM] shares were valued at $26.81 at the most recent close of the market. An investor can expect a potential return of 134.99% based on the average BEAM price forecast.
Analyzing the BEAM fundamentals
According to Beam Therapeutics Inc [NASDAQ:BEAM], the company’s sales were 352.57M for trailing twelve months, which represents an -41.48% plunge. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -0.52%, Pretax Profit Margin comes in at -0.4%, and Net Profit Margin reading is -0.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.16 and Total Capital is -0.17. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.11 points at the first support level, and at 23.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.69, and for the 2nd resistance point, it is at 28.56.
Ratios To Look Out For
It is important to note that Beam Therapeutics Inc [NASDAQ:BEAM] has a current ratio of 5.81. On the other hand, the Quick Ratio is 5.81, and the Cash Ratio is 1.65. Considering the valuation of this stock, the price to sales ratio is 6.27, the price to book ratio is 2.59.
Transactions by insiders
Recent insider trading involved Simon Amy, Chief Medical Officer, that happened on Jul 02 ’24 when 748.0 shares were sold. Chief Medical Officer, Simon Amy completed a deal on Jul 01 ’24 to sell 502.0 shares. Meanwhile, CEO Evans John M. sold 60000.0 shares on Jun 27 ’24.
